In an early clinical trial testing the novel therapy Alpha DaRT for recurrent glioblastoma, the first three patients given the radiation treatment all showed a…

Liraltagene autoleucel (lira-cel), an experimental cell therapy in clinical development for recurrent ovarian cancer, has been tolerated well so far in an early clinical trial,…

Cellcentric has raised $220 million in financing to support two clinical trials testing its potentially first-in-class oral therapy inobrodib in people with hard-to-treat…